Methazolamide
 OpenBabel02212023462D

 14 14  0  0  0  0  0  0  0  0999 V2000
    0.5678    1.9393    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.5678    1.1143    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.2352    0.6294    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.9803   -0.1553    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1553   -0.1553    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0997    0.6294    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8843    0.8843    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4974    0.3323    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2820    0.5872    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3259   -0.4747    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4652   -0.8227    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    1.9501   -1.4901    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.7977   -1.3076    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.1326   -0.3378    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0  0  0  0
  2  3  1  0  0  0  0
  2  6  1  0  0  0  0
  3  4  2  0  0  0  0
  4  5  1  0  0  0  0
  4 11  1  0  0  0  0
  5  6  1  0  0  0  0
  6  7  2  3  0  0  0
  7  8  1  0  0  0  0
  8  9  2  0  0  0  0
  8 10  1  0  0  0  0
 11 12  2  0  0  0  0
 11 13  2  0  0  0  0
 11 14  1  0  0  0  0
M  END
>  <CdId>
141

>  <Mol Weight>
236.272

>  <Formula>
C5H8N4O3S2

>  <ID>
T0106

>  <Name>
Methazolamide

>  <Synonyms>
L584601

>  <CAS>
554-57-4

>  <Approved status>
FDA

>  <Disease>
Metabolism

>  <Indication>
Type 2 Diabetes Mellitus

>  <Pathways>
Metabolism

>  <Target>
Carbonic Anhydrase inhibitor

>  <Receptor>
bCAIV; hCAI; hCAII

$$$$
